Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | THRA | P10827 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10161340 | 0.89 | THRA (0.42) | MAPTTDP1ALDH1A1LMNAHPGD | |
| SCHEMBL10160847 | 0.82 | CA12 (0.41) | MAPTALDH1A1HPGDGAAPKM | |
| SCHEMBL10196157 | 0.82 | THRA (0.40) | MAPTTDP1HPGDTP53TSHR | |
| SCHEMBL10161449 | 0.81 | MAPT (0.54) | MAPTTDP1ALDH1A1LMNAHPGD | |
| SCHEMBL31636665 | 0.78 | USP2 (0.49) | MAPTTDP1ALDH1A1LMNAHPGD | |
| SCHEMBL31636486 | 0.78 | ALDH1A1 (0.51) | MAPTTDP1ALDH1A1LMNAHPGD | |
| SCHEMBL10161339 | 0.76 | MRGPRX4 (0.46) | MAPTTDP1ALDH1A1LMNAHPGD | |
| SCHEMBL10161338 | 0.76 | HPGD (0.46) | MAPTTDP1ALDH1A1LMNAHPGD | |
| SCHEMBL10160846 | 0.76 | CA12 (0.46) | MAPTALDH1A1LMNAHPGDUSP2 | |
| SCHEMBL10160835 | 0.75 | L3MBTL1 (0.41) | MAPTTDP1ALDH1A1LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115819-A1 | Pentacycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115819-A1 | Pentacycline Compounds | TSLP, IL5, IL17A | MAPT 734/4885TDP1 2230/4885ALDH1A1 1598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.